 |
|
Targeted UV-B Phototherapy for Plaque-type Psoriasis
Pravit Asawanonda, MD, DSc;
Akkrawat Chingchai, MD;
Pawinee Torranin, MD
Arch Dermatol. 2005;141:1542-1546.
Objective To determine whether targeted UV-B phototherapy is efficacious and safe in the treatment of localized psoriasis and whether there is a dose-response relationship.
Design Randomized, evaluator-blind, controlled study.
Setting Dermatology clinic in a large university-based hospital in Bangkok, Thailand.
Patients Fourteen patients with stable, localized, plaque-type psoriasis.
Interventions Patients were randomized to receive different fluences of targeted UV-B phototherapy 3 times weekly based on predetermined minimal erythema doses (MEDs). Treatment fluences were constant throughout the study period of 4 weeks. Follow-up was carried out until lesions returned to original state.
Main Outcome Measures Modified psoriasis area and severity index.
Results All fluences of UV-B produced some clinical improvement and were very well tolerated. Fluences ranging from 1 to 6 multiples of MEDs resulted in clearance of lesions in some patients with 6 MEDs producing clearance in 77% of patients. The number of treatments required to clear psoriatic lesions when 2 to 6 MEDs were used was 5.0 to 6.1 treatments. The only adverse events observed were erythema, which was asymptomatic in most subjects, and hyperpigmentation.
Conclusions Incoherent, targeted UV-B phototherapy is a safe and efficacious treatment modality for localized psoriasis. Its value in other UV-B responsive conditions should be further investigated.
Author Affiliations: Division of Dermatology (Drs Asawanonda and Chingchai), Department of Medicine (Dr Torranin), Chulalongkorn University, Bangkok, Thailand.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Targeted UV-B Phototherapy: When and Why to Start
Torello Lotti, Riccardo Rossi, and Piero Campolmi
Arch Dermatol. 2006;142(7):933-934.
EXTRACT
| FULL TEXT
Targeted UV-B Phototherapy: When and Why to Start—Reply
Pravit Asawanonda, Akrawat Chingchai, and Pawinee Torranin
Arch Dermatol. 2006;142(7):934.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Impact of Obesity and Smoking on Psoriasis Presentation and Management
Mark D. Herron, Michael Hinckley, Matthew S. Hoffman, Jason Papenfuss, Christopher B. Hansen, Kristina P. Callis, and Gerald G. Krueger
Arch Dermatol. 2005;141(12):1527-1534.
ABSTRACT
| FULL TEXT
Prevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study
Joel M. Gelfand, Rachel Weinstein, Steven B. Porter, Andrea L. Neimann, Jesse A. Berlin, and David J. Margolis
Arch Dermatol. 2005;141(12):1537-1541.
ABSTRACT
| FULL TEXT
Dose-Response and Time-Course Characteristics of UV-A1 Erythema
Paula E. Beattie, Robert S. Dawe, James Ferguson, and Sally H. Ibbotson
Arch Dermatol. 2005;141(12):1549-1555.
ABSTRACT
| FULL TEXT
Soak and Smear: A Standard Technique Revisited
Ari Benjamin Gutman, Albert M. Kligman, Joslyn Sciacca, and William D. James
Arch Dermatol. 2005;141(12):1556-1559.
ABSTRACT
| FULL TEXT
Relationship Between Smoking and the Clinical Severity of Psoriasis
Cristina Fortes, Simona Mastroeni, Karen Leffondré, Francesca Sampogna, Franco Melchi, Eva Mazzotti, Paolo Pasquini, Damiano Abeni, and for the IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Study Group
Arch Dermatol. 2005;141(12):1580-1584.
ABSTRACT
| FULL TEXT
Advances in Psoriasis
Mark G. Lebwohl
Arch Dermatol. 2005;141(12):1589-1590.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Targeted UV-B Phototherapy: When and Why to Start.
Lotti et al.
Arch Dermatol 2006;142:933-934.
FULL TEXT
Targeted UV-B Phototherapy: When and Why to Start--Reply
Asawanonda et al.
Arch Dermatol 2006;142:934-934.
FULL TEXT
Advances in Psoriasis
Lebwohl
Arch Dermatol 2005;141:1589-1590.
FULL TEXT
|
